Withdrawals land mid-treatment, and interruption is the mechanism that undoes results.
Employer plans have continued to narrow or drop weight-management GLP-1 coverage at renewal, affecting large numbers of insured patients through 2025 and 2026. Diabetes indications are generally unaffected; the weight-management category is what gets cut.
The clinical problem is timing. Withdrawal happens at a plan-year boundary rather than at a point that makes sense in treatment, so patients lose coverage mid-course. The withdrawal trial evidence is unambiguous about what follows an interruption.
If your coverage is ending, price the cash market before your last covered fill rather than after it. The gap between the cheapest verified compounded route and brand self-pay is large enough that many people who stop for cost did not need to.
Categorical exclusions cannot be appealed on medical necessity, because they are plan design rather than a coverage determination. Knowing which you are facing saves weeks.
Sources
- Coverage withdrawal reporting and plan documentation, 2025–2026
Dated 2026-05-10. If this item is out of date or wrong, tell us through contact and the change is logged in corrections.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.